Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics

British Journal of Cancer

Volumn 81, Issue 5, 1999, Pages 760-768

  Newell, D R ^a   Burtles, S S ^b   Fox, B W ^c   Jodrell, D I ^c   Connors, T A ^d  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

^d UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Phase I trials; Preclinical toxicology; Starting dose

Indexed keywords

1 AZIRIDINO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 2,5 DIAZIRIDINYL 3,6 BIS(2 HYDROXYETHYLAMINO) 1,4 BENZOQUINONE; 3,4 DIHYDROXYBENZOHYDROXAMIC ACID; 4 (3,3 DIMETHYL 1 TRIAZENO)BENZOIC ACID; AMPHETHINILE; ANTINEOPLASTIC AGENT; BRYOSTATIN; ETOPOFOS; LEPTOMYCIN B; LOSOXANTRONE; MESYLMESYLIC ACID 2 CHLOROETHYL ESTER; MITOFLAXONE; MITOFLAXONE 2 DIETHYLAMINOETHYL ESTER; MITOZOLOMIDE; NOLATREXED; PENCLOMEDINE; SATRAPLATIN; TEMOZOLOMIDE; TRIMELAMOL;

ALOPECIA; ANIMAL EXPERIMENT; ARTICLE; BLOOD TOXICITY; CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DATA ANALYSIS; DIARRHEA; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FEMALE; FEVER; FLUSHING; HUMAN; HYPOTENSION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; LETHARGY; LIVER TOXICITY; MALAISE; MALE; MAXIMUM PERMISSIBLE DOSE; MOUSE; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PAIN; PHASE 1 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; QUANTITATIVE ASSAY; RASH; RAT; RIGOR; SIDE EFFECT; SKIN TOXICITY; THORAX PAIN; TOXICITY TESTING; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MICE; PREDICTIVE VALUE OF TESTS; RATS; RETROSPECTIVE STUDIES; TOXICITY TESTS;

EID: 0032748041     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690761     Document Type: Article

References (49)

1. Arbuck SG (1996) Workshop on Phase I study design. Ann Oncol 7: 567-573
2. Betteridge RF, Bosanquet AG and Gilby ED (1990) Pharmacokinetics of 2,5-diaziridinyl-3,6-bis(2-hydroxyethylamino) 1,4-benzoquinone (BZQ. NSC224070) during a Phase I clinical trial. Eur J Cancer 26: 107-112
3. Burtles SS, Newell DR, Henrar REC and Connors TA (1995) Revisions of general guidelines Cur the preclinical toxicology of new cytotoxic anticancer agents in Europe. Eur J Cancer 31A: 408-410
4. Cartmichael J, Cantwell BMJ, Mannix KA, Veale D, Elford HL, Blackie R, Kerr DJ, Kaye SB and Harris AI. (1990) A Phase I and pharmacokinetic study of didox administered by 36 hour infusion. Br J Cancer 61: 447-450
5. Collins JM, Zaharko DS, Dedrick RL and Chabner BA (1986) Potential roles for preclinical pharmacology in Phase I clinical trials. Cancer Treat Rep 70: 73-80
6. Collins JM, Grieshaber CK and Chabner BA (1990) Pharmacologically guided Phase I clinical trials based upon preclinical drug development. J Natl Cancer Inst 82; 1321-1326
7. Decoster G, Stein G and Holdener EE (1990) Responses and toxic deaths in Phase I clinical trials. Ann Oncol 1: 175-181
8. DeGeorge JJ, Ahn C-H, Andrews PA, Brower ME, Giorgio DW, Goheer ME, Lee-Ham DY, McGuinn WD, Schmidt W, Sun CJ and Tripathi SC (1998) Regulatory considerations for preclinical development of anticancer drugs. Cancer Chemother Pharmacol 41: 173-185
9. Dent SF and Eisenhauer FA (1996) Phase I trial design: are new methodologies being put into practise? Ann Oncol 7; 561-566
10. EORTC Pharmacokinetics and Metabolism Group (1987) Pharmacokinetically guided dose escalation in Phase I clinical trials. Eur J Cancer 23: 1083-1087
11. Estey E, Hoth D, Simon R, Marsoni S, Leyland-Jones B and Wittes R (1986) Therapeutic response in Phase I trials of antineoplastic agents. Cancer Treat Rep 70; 1105-1115
12. Foster BJ, Newell DR, Graham MA, Gumbrell LA, Jenns KE, Kaye SB and Calvert All (1992) Phase I trial of the anthrapyrazole CI-941: prospective evaluation of pharmacologically guided dose-escalation. Eur J Cancer 28: 463-469
13. Foster BJ, Newell DR, Carmichael J, Harris AL, Gumbrell LA, Jones M, Gogard PM and Calvert AH (1993a) Preclinical, Phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277. Br J Cancer 67: 362-368.
14. Foster BJ, Newell DR, Gumbrell LA, Jenns KE and Calvert AH (1993b) Phase I trial with pharmacokinetics of CB10-277 given by 24 hours continuous infusion. Br J Cancer 67: 369-373
15. Freireich EJ, Gehan EA, Rall DP, Schmidt LH and Skipper HE (1966) Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man. Cancer Chemother Rep 50: 219-244
16. Goldsmith MA, Slavik M and Carter SK (1975) Quantitative prediction of drug toxicity in humans from toxicology in small and large animals. Cancer Res 35: 1354-1364
17. Grieshaber CK and Marsoni S (1986) Relationship of preclinical toxicology to findings in early clinical trials. Cancer Treat Rep 70: 65-72
18. Homan ER (1972) Quantitative relationships between toxic doses of antitumour chemotherapeutic agents in animals and man. Cancer Chemother Rep Part 3 3: 13-19
19. Norwich A, Holliday SB, Deacon JM and Peckham MJ (1986) A toxicity and pharmacokinetic study in man of the hypoxic-cell radiosensitizer RSU-1069. Br J Radiol 59: 1238-1240
20. Jayson GC, Crowther D, Prendiville J, McGown AT, Scheid C, Stern P, Young R, Brenchley P, Thang J, Owens S and Peltit GR (1995) A Phase I trial of bryostalin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. Br J Cancer 72: 461-468
21. Jodrell DI, Bowman A, Stewart M, Dunlop N, French R, MacLellan A, Cummings J and Smyih JF (1998) Dose-limiting neurotoxicity in a Phase I study of penelomedine (NSC 388720, CRC 88-04), a synthetic α-picoline derivative, administered intravenously. Br J Cancer 77; 808-811
22. Joint Steering Committee of the EORTC and CRC (1990) General guidelines for the preclinical toxicology of new cytotoxic anticancer agents in Europe. Eur J Cancer 26; 411-414
23. 6-trimethylmelamine). Cancer Rev 49; 5475-5479
24. Judson I, Briasoulis E, Raynaud F, Hanwell J, Berry C and Lacey H (1997) Phase I trial and pharmacokinetics of the tubulin inhibitor 1069C85, a synthetic agent binding at the colchicine site designed to overcome multidrug resistance. Br J Cancer 75: 608-613
25. Kerr DJ, Kaye SB, Graham J, Cassidy J, Harding M, Setanoians A, McGrath JC, Vezin WR, Cunningham D, Forrest G and Soukop M (1986) Phase I and pharmacokinetic study of LM975 (flavone acetic acid ester). Cancer Res 46: 3142-3146
26. Kerr DJ, Kaye SB, Cassidy J, Bradley C, Rankin EM, Adams L, Setanotans A, Young T, Forrest G, Soukop M and Clavel M (1987) Phase I and pharmacokinetic study of flavone acetic acid. Cancer Res 47: 6776-6781
27. McKeage MJ, Mistry P, Ward J, Boxall FE, Loh S, O'Neill C, Ellis P, Kelland LR, Morgan SE, Murrer B, Santabarbara P, Harrap KR and Judson IR (1995) A Phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration. Cancer Chemother Pharmacol 36: 451-458
28. McKeage MJ, Raynaud F, Ward J, Berry C, O'Dell D, Kelland LR, Murrer B, Santabarbara P, Harrap KR and Judson IK (1997) Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J Clin Oncol 15: 2691-2700
29. Mick R and Ratain MJ (1993) Model-guided determination of maximum tolerated dose in Phase I clinical trials: evidence for increased precision. J Natl Cancer Inst 85; 217-223
30. Milliard MJ, Newell DR, Mummaneni V, Igwemezie LN, Balmanno K, Charlton CJ, Gumbrell L. Lind MJ, Chapman F, Proctor M, Simmonds D, Cantwell BMJ, Taylor GA, McDaniel C, Winograd B, Kaul S, Barbaiya RH and Calvert AH (1995) Phase I and pharmacokinetic study of the water-soluble etoposide prodrug, etoposide phosphate (BMY-40481). Eur J Cancer 31A: 2409-2411
31. Newlands ES, Blackledge G, Slack JA, Goddard C, Brindley CJ, Holden L and Stevens MFG (1985) Phase I clinical trial of mitozolomide. Cancer Treat Rep 69: 801-805
32. Newlands ES, Blackledge GRP, Slack JA, Rustin GJS, Smith DB, Stuart NSA, Quarterman CP, Hoffman R, Stevens MFG, Brampton MH and Gibson AC (1992) Phase I trial of temozolomide (CCRG 81045; M&B 39831; NSC 362856). Br J Cancer 65: 287-291
33. Newlands ES, Rustin GJS and Brampton MH (1996) Phase I trial of elactocin. Br J Cancer 74: 648-649
34. O'Quigley J and Chevrel S (1991) Methods for dose finding studies in cancer clinical trials: a review and results of a Monte Carlo study. Stat Med 10: 1647-1664
35. Penta JS, Rozeneweig M, Guarino AM and Muggia FM (1979) Mouse and large animal toxicology studies of twelve antitumour agents: relevance to starting dose for Phase I clinical trials. Cancer Chemother Pharmacol 3: 97-101
36. Penta JS, Rosner GL and Trump DL (1992) Choice of starting dose and escalation for Phase I studies of antitumour agents. Cancer Chemother Pharmacol 31: 247-250
37. Phillip PA, Rea D, Thavasu P, Carmichael J, Stuart NSA, Rockett H, Talbot DC, Ganesan T, Pettit GR, Balkwill F and Harris AL (1993) Phase I study of bryostatin 1 : assessment of interleukin 6 and tumour necrosis factor α induction in vivo. J Natl Cancer Inst 85: 1812-1818
38. Prendiville J, Crowther D, Thatcher N, Woll PJ, Fox BW, McGown A. Testa N, Stem P, McDermott R, Potter M and Pettit GR (1993) A Phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer 68: 418-424
39. Rafi I, Taylor GA, Calvete JA, Boddy AV, Batmanno K, Bailey N, Lind M, Calvert AH, Webber S, Jackson RJ, Johnston A, Clendeninn N and Newell DR (1995) Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3,4-dihydro-2-amino-6-methyl-4-oxo-5-(4 pyridylthio)-quinazoline dihydrochloride (AG337) given hy 24-hour intravenous infusion. Clin Cancer Res 1: 1275-1284
40. Rali I, Boddy AV, Calvete JA, Taylor GA, Newell DR, Bailey NP, Lind MJ, Green M, Hine J, Johnston A, Clendeninn N and Calvert A11 (1998) Preclinical and Phase I clinical studies with the non-classical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumours. J Clin Oncol 16: 1131-1141
41. Ratain MJ, Mick R, Schilsky RL and Siegler M (1993) Statistical and ethical issues in the design and conduct of Phase I and Phase II clinical trials of new anticancer agents. J Natl Cancer Inst 85: 1637-1643
42. Rozeneweig M, Von Hoff DD, Staquet MJ, Schein PS, Penta JS, Goldin A, Muggia FM, Freireich EJ and DeVite VT (1981) Animal toxicology for early clinical trials with anticancer agents. Cancer Clin Trials 4: 21-28
43. Simon R, Freidlin B, Rubinstein L, Arbuck S, Collins J and Christian MC (1997) Accelerated titration designs for Phase I clinical trials in oncology. J Natl Cancer Inst 89: 1138-1147
44. Smith DB, Fox BW, Thatcher N, Steward WP, Scarffe JH, Wagstaff J, Vezin R and Crowther D (1987) Phase I clinical trial of methylene dimethyl sulfonate. Cancer Treat Rep 71: 817-820
45. Smith DB, Ewen C, MacKintosh J, Fox BW, Thatcher N, Scarffe JH, Vezin R and Crowther D (1988) A Phase I trial and pharmacokinetic study of amphethinite. Br J Cancer 57: 023-627
46. Stuart NSA, Crawford SM, Blackledge GRP, Newlands ES, Slack J, Hoffman R and Stevens MFG (1989) A Phase I study of meta-azidopyrimethamine etanesulphonate (MZPES): a new dihydrofolate reductase inhibitor. Cancer Chemother Pharmacol 23: 308-310
47. Vasey PA, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, Thomson AH, Murray LS, Hilditch TE, Murray T, Burtles S, Fraier D, Frigerio E and Cassidy J (1999) Clin Cancer Res 5: 83-94
48. Veale D, Carmichael J, Cuntwell BMJ, Elford BL, Blackie R, Kerr DJ, Kaye SB and Harris AL (1988) A Phase I and pharmacokinetic study of didox: a ribonucleotide reductase inhibitor. Br J Cancer 58: 70-72
49. Verweij J (1996) Starting dose levels for Phase I studies. Ann Oncol 7 (suppl. 1): 13